AMP Capital China JV pays dividends
The joint venture between big China insurer China Life and AMP Capital — China Life AMP Asset Management Company Limited — has taken its next step with the launch of its first mutual fund.
The new product, the China Life AMP Money Market Fund, will invest in a range of short-term investments such as liquid short-term bonds and cash deposits on behalf of both retail and institutional customers.
Commenting on the launch of the new fund, AMP Capital chief executive Stephen Dunne said he was pleased to see the product brought to market just months after the establishment of the joint venture arrangement.
"The China Life AMP Money Market Fund analyses macroeconomic factors, monetary policy and credit supply to make a judgement on the trend of the yield curve while taking into consideration liquidity and the risk profile of different instruments," he said.
"It will appeal to investors who are looking for both yield and liquidity. We are very pleased with the level of support we've seen and look forward to providing Chinese domestic investors with additional investment products down the track."
AMP Capital holds a 15 per cent stake in the joint venture while China Life Asset Management Company Limited holds the rest. It is China Life's first joint venture in mainland China with a foreign partner in funds management.
Recommended for you
Compared to four years ago when the divide between boutique and large licensees were largely equal, adviser movements have seen this trend shift in light of new licensees commencing.
As ongoing market uncertainty sees advisers look beyond traditional equity exposure, Fidante has found adviser interest in small caps and emerging markets for portfolio returns has almost doubled since April.
CoreData has shared the top areas of demand for cryptocurrency advice but finds investors are seeking advisers who actively invest in the asset themselves.
With regulators ‘raising the bar’ on retirement planning, Lonsec Research and Ratings has urged advisers to place greater focus on sequencing and longevity risk as they navigate clients through the shifting landscape.
